You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

Litigation Details for Gilead Sciences, Inc. v. Lupin Limited (D. Del. 2021)

✉ Email this page to a colleague

« Back to Dashboard

Gilead Sciences, Inc. v. Lupin Limited (D. Del. 2021)

Docket	⤷ Sign Up	Date Filed	2021-11-16
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Parties	GILEAD SCIENCES, INC.
Patents	10,039,718
Attorneys	Irena Royzman
Firms	Phillips, Goldman, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Small Molecule Drugs cited in Gilead Sciences, Inc. v. Lupin Limited

The small molecule drugs covered by the patent cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .

Details for Gilead Sciences, Inc. v. Lupin Limited (D. Del. 2021)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2021-11-16	1	Complaint	U.S. Patent No. 10,039,718 (the “’718 patent”) and U.S. Patent No. 10,786,518 (the “’518 patent”) (together…Orange Book Patents- In-Suit”), and U.S. Patent No. 8,497,396 (the “’396 patent”) and U.S. Patent No. 9,428,473…“’473 patent”) (together, the “Process Patents-In-Suit”) (all patents collectively, the “Patents-In- …the expiration of the ’718 patent, ’518 patent, ’396 patent and ’473 patent (including such actions by… infringement of the ’718 patent, ’518 patent, ’396 patent and ’473 patent under 35 U.S.C. §§ 271 (a)	External link to document
2023-07-07	141	Notice of Service	Invalidity Contentions Regarding U.S. Patent No. 10,039,718 (the 718 Patent) filed by Lupin Limited, Lupin Pharmaceuticals…16 November 2021 1:21-cv-01621 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-08-10	149	Notice of Service	Daniel R. Kuritzkes, M.D. Regarding U.S. Patent No. 10,039,718, (5) Opening Expert Report of Leah Appel…Appel, Ph.D., Regarding Validity of U.S. Patent No. 10,039,718 filed by Gilead Sciences Ireland UC, Gilead… Kuritzkes, M.D. Regarding Infringement of U.S. Patent No. 10,786,518 and Objective Indicia of Non-obviousness…Regarding Objective Indicia of Nonobviousness of U.S. Patent No. 10,786,518, (3) Expert Report of Gregory K.…16 November 2021 1:21-cv-01621 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-08-10	150	Notice of Service	.D., Sc. Regarding the Validity of U.S. Patent No. 10,039,718 filed by Lupin Limited, Lupin Pharmaceuticals…Lynne Thio, M.D. Regarding the Validity of U.S. Patent No. 10,786,518, the [CONFIDENTIAL] Expert Report…. Regarding the Enablement of Prior Art to U.S. Patent No. 10,786,518, and the [CONFIDENTIAL] Expert report…16 November 2021 1:21-cv-01621 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-10-19	180	Notice of Service	Expert Report of Leah Appel, Ph.D., Regarding U.S. 10,039,718; (2) Rebuttal Expert Report of Dr. Daniel R. …. Kuritzkes, M.D. Regarding Validity of U.S. Patent No. 10,786,518; and (3) Rebuttal Expert Report of …Williams III, Ph.D., Regarding the Validity of U.S. Patent No. 10,786,518 filed by Gilead Sciences Ireland…16 November 2021 1:21-cv-01621 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2023-10-20	181	Notice of Service	Regarding Secondary Considerations of US Patent 10,039,718; [CONFIDENTIAL] Rebuttal Report of Graham …Buckton Regarding Secondary Considerations of US Patent 10,786,518; [CONFIDENTIAL] Rebuttal Expert Report…Infringement and Secondary Considerations of US Patent 10,786,518 filed by Lupin Limited, Lupin Pharmaceuticals…16 November 2021 1:21-cv-01621 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.